No Data
Express News | AIM ImmunoTech Announces New Pre-Clinical Data Showing Ampligen As Part Of Combination Therapy Slows Melanoma Tumor Growth And Improves Survival In Mouse Model
Express News | Aim Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
AIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination Therapy
Express News | Todd Deutscha: Reiterates It Is Not Their Intention to Acquire Control Stake in AIM ImmunoTech's Shares of Common Stock
Express News | Todd Deutsch Says Excpect AIM ImmunoTech Board to Promptly Amend Bylaws in Way That Is Consistent With Fiduciary Duties
Express News | Todd Deutsch Says Significant Change in AIM ImmunoTech's Board Is Urgently Needed - SEC Filing
No Data
HotShot369 OP : Ignore the aztr. sold some for profit and dilute cost went down
HotShot369 OP : Some of these plan to hold for a few days to 2 weeks
HotShot369 OP : now just realized I got posted everywhere I bought. WHAT THE FLIP
HotShot369 OP : I'm also watching rnaz
HotShot369 OP : mbio too
View more comments...